The oral iron chelator, deferasirox, reverses the age-dependent alterations in iron and amyloid-β homeostasis in rat brain: Implications in the therapy of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 49, Issue 3, 2015, Pages 681-693

  Banerjee, Priyanjalee ^a   Sahoo, Arghyadip ^a   Anand, Shruti ^a   Bir, Aritri ^b   Chakrabarti, Sasanka ^b  

^a Institute of Post Graduate Medical Education and Training   (India)

^b Icare institute of Medical Sciences   (India)

Author keywords

Alzheimer's disease; Amyloid 42; brain aging; ferritin; iron; oxidative stress; transferrin receptor

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; CD71 ANTIGEN; DEFERASIROX; FERRITIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRON; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA; AMYLOID BETA-PROTEIN (1-42); BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; PEPTIDE FRAGMENT; SECRETASE; TFR1 PROTEIN, RAT; TRANSFERRIN RECEPTOR; TRIAZOLE DERIVATIVE;

AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; BRAIN FUNCTION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; IRON METABOLISM; IRON STORAGE; IRON TRANSPORT; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN HOMEOSTASIS; PROTEIN METABOLISM; PROTEIN PROCESSING; RAT; ANIMAL; BRAIN; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; ORAL DRUG ADMINISTRATION; PROTEIN CARBONYLATION; SPECTROPHOTOMETRY; WISTAR RAT;

ADMINISTRATION, ORAL; AGING; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BENZOATES; BRAIN; FERRITINS; GENE EXPRESSION REGULATION; IRON; IRON CHELATING AGENTS; NEPRILYSIN; NF-KAPPA B; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PROTEIN CARBONYLATION; RATS; RATS, WISTAR; RECEPTORS, TRANSFERRIN; SPECTROPHOTOMETRY; TRIAZOLES;

EID: 84949944900     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150514     Document Type: Article

References (79)

1. Mayeux R, Stern Y (2012) Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med 2, a006239.
2. Selkoe DJ (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81, 741-766.
3. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1, a006189.
4. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: A practical approach. Acta Neuropathol 123, 1-11.
5. Dekosky ST (2002) Neurobiology and molecular biology of Alzheimer's disease. Rev Neurol 35, 752-760.
6. Butterfield DA, Perluigi M, Sultana R (2006) Oxidative stress in Alzheimer's disease brain: New insight from redox pro-teomics. Eur J Pharmacol 545, 39-50.
7. Heppner FL, Ransohoff RM, Becher B(2015) Immune attack: The role of inflammation in Alzheimer disease. Nat Rev Neurosci 16, 358-372.
8. Chakrabarti S, Sinha M, Thakurta IG, Banerjee P, Chattopad-hyay M (2013) Oxidative stress and amyloid beta toxicity in Alzheimer's disease: Intervention in a complex relationship by antioxidants. Curr Med Chem 20, 4648-4664.
9. Reddy PH, Beal MF (2008) Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 14, 45-53.
10. Swerdlow RH (2007) Pathogenesis of Alzheimer's disease. Clin Interv Aging 2, 347-359.
11. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5, 863-873.
12. Lovell MA, Markesbery WR (2006) Amyloid beta peptide, 4-hydroxynonenal and apoptosis. Curr Alzheimer Res 3, 359-364.
13. Rogers JT, Lahiri DK (2004) Metal and inflammatory targets for Alzheimer's disease. Curr Drug Targets 5, 535-551.
14. Smith MA, Harris PLR, Sayre LM, Perry G (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 94, 9866-9868.
15. Raven EP, Lu PH, Tishler TA, Heydari P, Bartzokis G (2013) Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer's disease detected in vivo with magnetic resonance imaging. J Alzheimers Dis 37, 127-136.
16. Sampietro M, Caputo L, Casatta A, Meregalli M, Pellagatti A, Tagliabue J, Annoni G, Vergani C (2001) The hemochromatosis gene affects the age of onset of sporadic Alzheimer's disease. Neurobiol Aging 22, 563-568.
17. Bandyopadhyay S, Rogers JT (2014) Alzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: Maintenance of brain iron homeostasis. Biochem Pharmacol 88, 486-494.
18. Rottkamp CA, Raina AK, Zhu X, Gaier E, Bush AI, Atwood CS, Chevion M, Perry G, Smith A (2001) Redox-active iron mediates amyloid-fj toxicity. Free Radic Biol Med 30, 447-450.
19. Bandyopadhyay S, Huang X, Lahiri DK, Rogers JT (2010) Novel drug targets based on metallobiology of Alzheimer's disease. Expert Opin Ther Targets 14, 1177-1197.
20. Maloney B, Ge YW, Greig N, Lahiri DK (2004) Presence of a "CAGA box" in the APP gene unique to amyloid plaque-forming species and absent in all APLP-1/2 genes: Implications in Alzheimer's disease. FASEB J18, 1288-1290.
21. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gun-shin H, Leiter L, McPhee J, Sarang SS, Utsuki T, Greig NH, Lahiri DK, Tanzi RE, Bush AI, Giordano T, Gullans SR (2002) An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 277, 45518-45528.
22. Bandyopadhyay S, Cahill C, Balleidier A, Huang C, Lahiri DK, Huang X, Rogers JT (2013) Novel 5' untranslated region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: Implications for down syndrome and Alzheimer's disease. PLoS One 8, e65978.
23. Cummings BJ, Su JH, Cotman CW, White R, Russell MJ (1993) Beta-amyloid accumulation in aged canine brain: A model of early plaque formation in Alzheimer's disease. Neurobiol Aging 14, 547-560.
24. Price JL, Morris JC (1999) Tangles and plaques in nonde-mented aging and "preclinical" Alzheimer's disease. Ann Neurol 45, 358-368.
25. Fukumoto H, Asami-Odaka A, Suzuki N, Shimada H, Ihara Y, Iwatsubo T (1996) Amyloid beta protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance of A beta 42(43) and association of A beta 40 with cored plaques. Am J Pathol 148, 259-265.
26. Lesne SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, Ashe KH (2013) Brain amyloid-fj oligomers in ageing and Alzheimer's disease. Brain 136, 1383-1398.
27. Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L (2014) The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol 13, 1045-1060.
28. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106, 1489-1499.
29. Dewachter I, van Dorpe J, Spittaels K, Tesseur I, Van Den Haute C, Moechars D, Van Leuven F (2000) Modeling Alzheimer's disease in transgenic mice: Effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice. Exp Gerontol 35, 831-841.
30. Hellstrom-Lindahl E, Ravid R, Nordberg A (2008) Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: Inverse correlation with Abeta levels. Neurobiol Aging 29, 210-221.
31. Zhao W, Zhang J, Davis EG, Rebeck GW (2014) Aging reduces glial uptake and promotes extracellular accumulation of Afj from a lentiviral vector. Front Aging Neurosci 6, 210.
32. Pascale CL, Miller MC, Chiu C, Boylan M, Caralopoulos IN, Gonzalez L, Johanson CE, Silverberg GD (2011) Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent. Fluids Barriers CNS 8, 21.
33. Piga A, Fracchia S, Lai ME, Cappellini MD, Hirschberg R, Habr D, Wegener A, Bouillaud E, Forni GL (2015) Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent fj thalassaemia. Br J Haematol 168, 882-890.
34. Chen CH, Shu KH, Yang Y (2015) Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload. Hematology 20, 304-310.
35. Pfaffl MW (2001) A new mathematical model for relative quantative real-time RT-PCR. Nucleic Acids Res 29, 2002-2007.
36. Riemer J, Hoepken HH, Czerwinska H, Robinson SR, Drin-gen R (2004) Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells. Anal Biochem 331, 370-375.
37. Thakurta IG, Chattopadhyay M, Ghosh A, Chakrabarti S (2012) Dietary supplementation with N-acetyl cysteine, a-tocopherol and a-lipoic acid reduces the extent of oxidative stress and proinflammatory state in aged rat brain. Biogeron-tology 13, 479-488.
38. Page M, Thorpe R (2002) Protein blotting by electroblotting, In The Protein Protocols Handbook, Walker JM, ed, Humana Press, New Jersey, pp. 317-319.
39. Oliveri C, Ocaranza MP, Campos X, Lavandero S, Jalil JE (2001) Angiotensin I-converting enzyme modulates neutral endopeptidase activity in the rat. Hypertension 38, 650-654.
40. Miners JS, Verbeek MM, Rikkert MO, Kehoe PG, Love S (2008) Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid. J Neurosci Methods 167, 229-236.
41. MacKenzie EL, Iwasaki K, Tsuji Y (2008) Intracellular iron transport and storage: From molecular mechanisms to health implications. Antioxid Redox Signal 10, 997-1030.
42. Mills E, Dong X-P, Wang F, Xu H (2010) Mechanisms of brain iron transport: Insight into neurodegeneration and CNS disorders. Future Med Chem 2, 51-64.
43. Zheng W, Monnot AD (2012) Regulation of brain iron and copper homeostasis by brain barrier systems: Implication in neurodegenerative diseases. Pharmacol Ther 133, 177-188.
44. Focht SJ, Snyder BS, Beard JL, Van Gelder W, Williams LR, Connor JR (1997) Regional distribution of iron, transferrin, ferritin, and oxidatively-modified proteins in young and aged Fischer 344 rat brains. Neuroscience 79, 255-261.
45. Hagemeier J, Geurts JJ, Zivadinov R (2012) Brain iron accumulation in aging and neurodegenerative disorders. Expert Rev Neurother 12, 1467-1480.
46. Kastman EK, Willette AA, Coe CL, Bendlin BB, Kosmatka KJ, McLaren DG, Xu G, Canu E, Field AS, Alexander AL, Voytko ML, Beasley TM, Colman RJ, Weindruch RH, Johnson SC (2012) A calorie-restricted diet decreases brain iron accumulation and preserves motor performance in old rhesus monkeys. J Neurosci 32, 11897-11904.
47. Mesquita SD, Ferreira AC, Sousa JC, Santos NC, Correia-Neves M, Sousa N, Palha JA, Marques F (2012) Modulation of iron metabolism in aging and in Alzheimer's disease: Relevance of the choroid plexus. Front Cell Neurosci 6, 25.
48. Thomson AM, Rogers JT, Leedman PJ (1999) Iron-regulatory proteins, iron-responsive elements and ferritin mRNA translation. Int J Biochem Cell Biol 31, 1139-1152.
49. Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, Link G (2001) ICL670A: A new synthetic oral chelator: Evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood 97, 1115-1122.
50. Dexter DT, Statton SA, Whitmore C, Freinbichler W, Weinberger P, Tipton KF, Della Corte L, Ward RJ, Crichton RR (2011) Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. J Neural Transm 118, 223-231.
51. Tacchini L, Bianchi L, Bernelli-Zazzera A, Cairo G (1999) Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J Biol Chem 274, 24142-24146.
52. Tacchini L, Gammella E, De Ponti C, Recalcati S, Cairo G (2008) Role of HIF-1 and NF-kappaB transcription factors in the modulation of transferrin receptor by inflammatory and anti-inflammatory signals. J Biol Chem 283, 20674-20686.
53. Tsuji Y, Ayaki H, Whitman SP, Morrow CS, Torti SV, Torti FM (2000) Coordinate transcriptional and translational regulation of ferritin in response to oxidative stress. Mol Cell Biol 20, 5818-5827.
54. Wang J, Pantopoulos K (2011) Regulation of cellular iron metabolism. Biochem J 434, 365-381.
55. Torti FM, Torti SV (2002) Regulation of ferritin genes and protein. Blood 99, 3505-3516.
56. Hirose W, Ikematsu K, Tsuda R (2003) Age-associated increases in heme oxygenase-1 and ferritin immunoreactivity in the autopsied brain. Leg Med (Tokyo) 5, S360-S366.
57. Rogers JT, Bush AI, Cho HH, Smith DH, Thomson AM, Friedlich AL, Lahiri DK, Leedman PJ, Huang X, Cahill CM (2008) Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: Riboregulation against neural oxidative damage in Alzheimer's disease. Biochem Soc Trans 36, 1282-1287.
58. Banerjee P, Sahoo A, Anand S, Ganguly A, Righi G, Bovi-celli P, Saso L, Chakrabarti S (2014) Multiple mechanisms of iron-induced amyloid beta-peptide accumulation in SHSY5Y cells: Protective action of negletein. Neuromolecular Med 16, 787-798.
59. Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, Irizarry MC (2004) Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol 164, 719-725.
60. Chami L, Checler F (2012) BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and fj-amyloid production in Alzheimer's disease. Mol Neurodegener 7, 52.
61. Hayden MS, Ghosh S (2004) Signaling to NF-kB. Genes Dev 18, 2195-2224.
62. Bagh MB, Maity AK, Roy A, Chakrabarti S (2008) Dietary supplementation with Nacetylcysteine, alpha-tocopherol and alpha-lipoic acid prevents age related decline in Na(+), K(+)-ATPase activity and associated peroxidative damage in rat brain synaptosomes. Biogerontology 9, 421-428.
63. Zaidi A, Michaelis ML (1999) Effects of reactive oxygen species on brain synaptic plasma membrane Ca(2+)-ATPase. Free Radic Biol Med 27, 810-821.
64. Wang DS, Iwata N, Hama E, Saido TC, Dickson DW (2003) Oxidized neprilysin in aging and Alzheimer's disease brains. Biochem Biophys Res Commun 310, 236-241.
65. Thakurta IG, Banerjee P, Bagh MB, Ghosh A, Sahoo A, Chattopadhyay S, Chakrabarti S (2014) Combination of N-acetylcysteine, a-lipoic acid and a-tocopherol substantially prevents the brain synaptosomal alterations and memory and learning deficits of aged rats. Exp Gerontol 50, 19-25.
66. Kaur U, Banerjee P, Bir A, Sinha M, Biswas A, Chakrabarti S (2015) Reactive oxygen species, redox signaling and neuroin-flammation in Alzheimer's disease: The NF-KB connection. Curr Topics Med Chem 15, 446-457.
67. Gnjec A, Fonte JA, Atwood C, Martins RN (2002) Transition metal chelator therapy - A potential treatment for Alzheimer's disease? Front Biosci 7, d1016-d1023.
68. Liu G, Garrett MR, Men P, Zhu X, Perry G, Smith MA (2005) Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim Biophys Acta 1741, 246-252.
69. Cuajungco MP, Frederickson CJ, Bush AI (2005) Amyloid-beta metal interaction and metal chelation. Subcell Biochem 38, 235-254.
70. White AR, Multhaup G, Maher F, Bellingham S, Camakaris J, Zheng H, Bush AI, Beyreuther K, Masters CL, Cappai R (1999) The Alzheimer's disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures. J Neurosci 19, 9170-9179.
71. Kong GK, Miles LA, Crespi GA, Morton CJ, Ng HL, Barnham KJ, McKinstry WJ, Cappai R, Parker MW (2008) Copper binding to the Alzheimer's disease amyloid precursor protein. Eur Biophys J 37, 269-279.
72. Smith DG, Cappai R, Barnham KJ (2007) The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim Biophys Acta 1768, 1976-1990.
73. Nakamura M, Shishido N, Nunomura A, Smith MA, Perry G, Hayashi Y, Nakayama K, Hayashi T (2007) Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron. Biochemistry 46, 12737-12743.
74. Bousejra-ElGarah F, Bijani C, Coppel Y, Faller P, Hureau C (2011) Iron(II) binding to amyloid-fj, the Alzheimer's peptide. Inorg Chem 50, 9024-9030.
75. Everett J, Cespedes E, Shelford LR, Exley C, Collingwood JF, Dobson J, van der Laan G, Jenkins CA, Arenholz E, Telling ND (2014) Ferrous iron formation following the co-aggregation of ferric iron and the Alzheimer's disease peptide fj-amyloid (1-42). J R Soc Interface 11, 20140165.
76. Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, Andrews DF (1991) Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337, 1304-1308.
77. Bareggi SR, Cornelli U (2012) Clioquinol: Review of its mechanisms of action and clinical uses in neurodegenerative disorders. CNS Neurosci Ther 18, 41-46.
78. Cancado R, Melo MR, de Moraes Bastos R, Santos PC, Guerra-Shinohara EM, Chiattone C, Ballas SK (2015) Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: Results of a 1-yr Phase 2 study. Eur J Haematol. doi: 10.1111/ejh.12530
79. Cassinerio E, Roghi A, Orofino N, Pedrotti P, Zanaboni L, Poggiali E, Giuditta M, Consonni D, Cappellini MD (2015) A 5-year follow-up in deferasirox treatment: Improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients. Ann Hematol 94, 939-945.